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ABSTRACT: Recent case-series of small size implied a pathophysiological association between coronavirus disease 2019 
(COVID-19) and severe large-vessel acute ischemic stroke. Given that severe strokes are typically associated with poor 
prognosis and can be very efficiently treated with recanalization techniques, confirmation of this putative association is 
urgently warranted in a large representative patient cohort to alert stroke clinicians, and inform pre- and in-hospital acute 
stroke patient pathways. We pooled all consecutive patients hospitalized with laboratory-confirmed COVID-19 and acute 
ischemic stroke in 28 sites from 16 countries. To assess whether stroke severity and outcomes (assessed at discharge or at 
the latest assessment for those patients still hospitalized) in patients with acute ischemic stroke are different between patients 
with COVID-19 and non-COVID-19, we performed 1:1 propensity score matching analyses of our COVID-19 patients with 
non-COVID-19 patients registered in the Acute Stroke Registry and Analysis of Lausanne Registry between 2003 and 
2019. Between January 27, 2020, and May 19, 2020, 174 patients (median age 71.2 years; 37.9% females) with COVID-19 
and acute ischemic stroke were hospitalized (median of 12 patients per site). The median National Institute of Health 
Stroke Scale was 10 (interquartile range [IQR], 4–18). In the 1:1 matched sample of 336 patients with COVID-19 and non-
COVID-19, the median National Institute of Health Stroke Scale was higher in patients with COVID-19 (10 [IQR, 4–18] 
versus 6 [IQR, 3–14]), P=0.03; (odds ratio, 1.69 [95% CI, 1.08–2.65] for higher National Institute of Health Stroke Scale 
score). There were 48 (27.6%) deaths, of which 22 were attributed to COVID-19 and 26 to stroke. Among 96 survivors with 
available information about disability status, 49 (51%) had severe disability at discharge. In the propensity score-matched 
population (n=330), patients with COVID-19 had higher risk for severe disability (median mRS 4 [IQR, 2–6] versus 2 [IQR, 
1–4], P<0.001) and death (odds ratio, 4.3 [95% CI, 2.22–8.30]) compared with patients without COVID-19. Our findings 
suggest that COVID-19 associated ischemic strokes are more severe with worse functional outcome and higher mortality 
than non-COVID-19 ischemic strokes.
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Coronavirus disease 2019 (COVID-19), a viral disease caused by the severe acute respiratory syndrome coronavirus 2, may predispose patients to arterial 
thrombotic complications mediated by inflammation, 
endothelial dysfunction, thrombin generation, and platelet 
activation.f Three recent case-series of small size implied 
a pathophysiological association between COVID-19 
and severe large-vessel acute ischemic stroke (AIS).2–4 
Given that severe strokes are typically associated with 
poor prognosis and can be very efficiently treated with 
recanalization techniques, confirmation of this putative 
association is urgently warranted in a large representa-
tive patient cohort to alert stroke clinicians and inform 
pre- and in-hospital acute stroke patient pathways.
We pooled all consecutive patients hospitalized with 
laboratory-confirmed COVID-19 and AIS in 28 sites from 
16 countries. We excluded patients who were infected 
after the onset of stroke. Nineteen (70.4%) sites were 
reference hospitals for patients with COVID-19. A pre-
specified form was used to register anonymized patient 
data. To assess whether stroke severity (estimated by the 
National Institute of Health Stroke Scale) and outcomes 
(assessed by the modified Rankin Scale, at discharge or 
at the latest assessment for those patients still hospital-
ized) in patients with AIS are different between patients 
with and without COVID-19, we performed 1:1 propen-
sity score matching analyses of our COVID-19 patients 
with non-COVID-19 patients registered in the Acute 
Stroke Registry and Analysis of Lausanne5 between 
2003 and 2019. For the propensity score matching 
analysis of stroke severity, patients were matched with-
out replacement on a set of prespecified covariates, 
including demographics (age, sex), stroke risk factors, 
and comorbidities (hypertension, diabetes mellitus, atrial 
fibrillation, coronary artery disease, heart failure, cancer, 
previous stroke, smoking, obesity, dyslipidemia). For the 
propensity score matching analysis of outcomes, the 
type of intervention and main stroke symptoms (motor 
symptoms, sensory symptoms, dysarthria, and aphasia) 
were additionally matched (further details on statistical 
methods are available in the supplementary material). 
The Global COVID-19 Stroke registry was approved 
by the Institutional Review Board of the co-ordinating 
site (Larissa University Hospital). Informed consent was 
waived as this was an observational study on pseudony-
mized data. Requests to access the data set from quali-
fied researchers trained in human subject confidentiality 
protocols may be sent to the first author.
Between January 27, 2020, and May 19, 2020, 174 
patients (median age 71.2 years; 37.9% females) with 
COVID-19 and AIS were hospitalized (median of 12 
patients per site). There were 45 patients aged >80 
years and 41 aged <64 years.
In 96% of the cases, COVID-19 was confirmed with 
PCR and in the others by serology. The most prevalent 
stroke risk factors and comorbidities were hyperten-
sion (68.4%), obesity (37.4%), and diabetes mellitus 
(31.03%). Previous stroke was reported in 20 (11.5%) 
patients. The median delay between the initiation of 
COVID-19 symptoms and stroke onset was 7 days 
(interquartile range [IQR]: 2–15). The most prevalent 
COVID symptoms were fever (55.2%,), cough (53.5%), 
and dyspnoea (43.7%).
The main stroke symptoms were motor (67.8%), dys-
arthria (46%), and sensory (42%). The median National 
Institute of Health Stroke Scale was 10 (IQR: 4–18). In 
the 1:1 matched sample of 336 patients with and with-
out COVID-19, the median National Institute of Health 
Stroke Scale was higher in patients with COVID-19 (10 
[IQR: 4–18] versus 6 [IQR: 3–14], P=0.03; odds ratio, 
1.69 [95% CI, 1.08–2.65] for higher National Institute of 
Health Stroke Scale score; Figure).
The vascular territory most frequently affected was 
the middle cerebral artery (in 93 out of 163 patients 
with available information). In the matched database 
(n=366), 132 of 168 patients with COVID-19 had 
a complete diagnostic workup towards stroke cause. 
Among those 132 patients, 30 (22.7%) and 10 (7.6%) 
had a large-artery or a lacunar stroke, respectively. In 
the non-COVID-19 matched cohort, we recorded 22 
(13.1%) patients with large-artery atherosclerosis and 
17 (10.2%) with lacunar stroke. Overall, we did not 
find a difference in the prevalence of large-artery and 
lacunar stroke between the 2 populations (nonpara-
metric χ2 test P=0.082).
In the overall population of the patients with COVID-
19, alteplase was administered in 34 (19.7%) of patients 
and endovascular thrombectomy was performed in 21 
(12.1%) patients (33 and 20 among the patients with 
COVID-19who were included in the matched analy-
sis, respectively). The outcomes per intervention in the 
matched cohort of patients with stroke with and without 
COVID-19 are presented in the Data Supplement. Any 
hemorrhagic transformation of the infarct was diagnosed 
in 22 patients, of whom 5 had been treated with intrave-
nous alteplase. Malignant brain edema was present in 4 
(5.1%) patients and 3 of these patients were treated with 
hemicraniectomy.
Among 112 patients who had pulmonary imaging 
with chest CT, 89.3% had lung opacities. Twenty-
seven patients (15.5%) were intubated, 40 (23%) 
were transferred to an intensive care unit, and 110 
(63.2%) were discharged from the hospital. There 
were 48 (27.6%) deaths, of which 22 were attributed 
Nonstandard Abbreviations and Acronyms
AIS acute ischemic stroke
COVID-19 coronavirus disease 2019
IQR interquartile range
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to COVID-19 and 26 to stroke. Among 96 survivors 
with available information about disability status, 49 
(51%) had severe disability at discharge. In the pro-
pensity score matched population (n=330), patients 
with COVID-19 had higher risk for severe disability 
(median modified Rankin Scale 4 [IQR: 2–6] versus 2 
[IQR: 1–4], P<0.001) and death (odds ratio, 4.3 [95% 
CI, 2.22–8.30]) compared with patients with non-
COVID-19 (Figure).
The strengths of this analysis are the large patient 
cohort, the multicentre international design, the inclu-
sion of all consecutive known COVID-19 AIS patients 
treated in each site, and the propensity score matching 
comparison with a non-COVID-19 AIS cohort. A limi-
tation of the study is that the propensity score match 
cohort was from a single site; however, as described 
in the supplemental material, our sensitivity analy-
sis for potential hidden bias in the matched database 
confirmed the robustness of the main findings. Even 
if this extra, unobserved indicator (ie, site of recruit-
ment) could affect the odds of a patient’s conditional 
classification to the case or control group by up to 
130% and in parallel was totally unrelated to all of the 
variables taken into consideration (demographic char-
acteristics, risk factors, comorbidities, stroke symptoms, 
and treatment), still our results of increased mortality 
and disability in patients with COVID-19 would not 
substantially change.
There are several potential explanations for the rela-
tion between COVID-19 associated ischemic strokes 
and increased stroke severity, which may co-exist. It 
was proposed that viral infections may cause a direct 
vasculopathic effect (endotheliopathy) or potenti-
ate the prothrombotic milieu via several mechanisms 
including immune-mediated platelet activation, dehy-
dration, and infection-induced cardiac arrhythmias.6 It 
is unclear whether the finding of increased severity in 
COVID-19 associated ischemic strokes applies to all 
ischemic stroke types or is mainly driven by an increase 
in large-vessel occlusion strokes, as implied by recent 
findings.2 Finally, it may be possible that the stay-at-
home recommendations/orders and the general fear of 
Figure. Matched populations of 
patients with coronavirus disease 
2019 (COVID-19) from the Global 
COVID-19 Stroke Registry and 
patients without COVID-19 from the 
Acute Stroke Registry and Analysis 
of Lausanne (ASTRAL) registry. 
The upper panel presents the distribution 
of the modified Rankin Scale scores. The 
lower panel presents the histogram and 
Kernel Density Estimates of the National 
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the hospital during the COVID-19 pandemic may have 
prevented patients with acute stroke with smaller defi-
cits from presenting to the hospital, although a recent 
study in Barcelona reported that initial stroke severity 
was not different between patients with stroke admit-
ted in March 2019 and March 2020.7
The increased stroke severity at admission in COVID-
19 associated stroke patients compared with the non-
COVID-19 cohort may explain the worse outcomes. The 
broad multi-system complications of COVID-19 including 
acute respiratory distress syndrome, cardiac arrhythmias, 
acute cardiac injury, shock, pulmonary embolism, cyto-
kine release syndrome and secondary infection,8 prob-
ably contribute further to the worse outcomes including 
higher mortality in these patients.
Our findings suggest that COVID-19 associated isch-
emic strokes are more severe with worse functional out-
come and higher mortality than non-COVID-19 ischemic 
strokes. The association between COVID-19 and severe 
stroke highlights the urgent need for studies aiming to 
uncover the underlying mechanisms and is relevant for 
prehospital stroke awareness and in-hospital acute stroke 
pathways during the current and future pandemics, since 
severe strokes have typically poor prognosis and can 
potentially be treated with recanalization techniques.
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